Predictive Patent

The granted patent covers the DRP methods for predicting clinical benefit from stenoparib based on gene-expression profiles derived from tumor samples, as well as methods for selecting patients most likely to benefit from stenoparib treatment using the stenoparib DRP test. This protection is crucial for the company's strategy to develop and commercialize stenoparib in the world's most important commercial markets.